Galmed Pharmaceuticals is undergoing a critical strategic pivot. Historically focused almost exclusively on developing its lead compound, Aramchol, for NASH (MASH) and liver fibrosis, the company is now expanding into gastrointestinal (GI) medical devices, cardiometabolic indications, and central nervous system (CNS) therapeutics. The definitive agreement to acquire Colospan Ltd. in June 2026 introduces a commercial-stage medical device (CG-100) with FDA Breakthrough Device Designation, providing a faster path to revenue. However, Galmed continues to face severe financial constraints, recurring operating losses, and an explicit going-concern warning from its auditors. While recent clinical milestones—such as a 500% bioavailability increase with its new Aramchol Meglumine formulation and promising preclinical data in cardiac fibrosis and Parkinson's disease—provide long-term optionality, the immediate dilution risks and high capital requirements justify a cautious Hold stance.